In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure

Peter Tajti; Khaldoon Alaswad; Dimitri Karmpaliotis; Farouc A. Jaffer; Robert W. Yeh; Mitul Patel; Ehtisham Mahmud; James W. Choi; M. Nicholas Burke; Anthony H. Doing; Catalin Toma; Barry Uretsky; Elizabeth Holper; R. Michael Wyman; David E. Kandzari; Santiago Garcia; Oleg Krestyaninov; Dmitrii Khelimskii; Michalis Koutouzis; Ioannis Tsiafoutis; Wissam Jaber; Habib Samady; Jeffrey W. Moses; Nicholas J. Lembo; Manish Parikh; Ajay J. Kirtane; Ziad A. Ali; Darshan Doshi; Iosif Xenogiannis; Bavana V. Rangan; Imre Ungi; Subhash Banerjee; Emmanouil S. Brilakis

doi:10.1016/j.amjcard.2018.04.021

In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure

Peter Tajti, Khaldoon Alaswad, Dimitri Karmpaliotis, Farouc A. Jaffer, Robert W. Yeh, Mitul Patel, Ehtisham Mahmud, James W. Choi, M. Nicholas Burke, Anthony H. Doing, Catalin Toma, Barry Uretsky, Elizabeth Holper, R. Michael Wyman, David E. Kandzari, Santiago Garcia, Oleg Krestyaninov, Dmitrii Khelimskii, Michalis Koutouzis, Ioannis TsiafoutisWissam Jaber, Habib Samady, Jeffrey W. Moses, Nicholas J. Lembo, Manish Parikh, Ajay J. Kirtane, Ziad A. Ali, Darshan Doshi, Iosif Xenogiannis, Bavana V. Rangan, Imre Ungi, Subhash Banerjee, Emmanouil S. Brilakis

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The frequency and outcomes of patients who underwent chronic total occlusion (CTO) percutaneous coronary intervention (PCI) of more than one CTO during the same procedure have received limited study. We compared the clinical and angiographic characteristics and procedural outcomes of patients who underwent treatment of single versus >1 CTOs during the same procedure in 20 centers from the United States, Europe, and Russia. A total of 2,955 patients were included: mean age was 65 ± 10 years and 85% were men with high prevalence of previous myocardial infarction (46%), and previous coronary artery bypass graft surgery (33%). More than one CTO lesions were attempted during the same procedure in 58 patients (2.0%) and 70% of them were located in different major epicardial arteries. Compared with patients who underwent PCI of a single CTO, those who underwent PCI of >1 CTOs during the same procedure had similar J-CTO (2.4 ± 1.3 vs 2.5 ± 1.3, p = 0.579) and Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (1.5 ± 1.2 vs 1.3 ± 1.0 p = 0.147) scores. The multi-CTO PCI group had similar technical success (86% vs 87%, p = 0.633), but higher risk of in-hospital major complications (10.3% vs 2.7%, p = 0.005), and consequently numerically lower procedural success (79% vs 85%, p = 0.197). The multi-CTO PCI group had higher in-hospital mortality (5.2% vs 0.5%, p = 0.005) and stroke (5.2%vs 0.2%, p <0.001), longer procedure duration (162 [117 to 242] vs 122 [80 to 186] minutes, p <0.001) and higher radiation dose (3.6 [2.1 to 6.4] vs 2.9 [1.7 to 4.7] Gray, p = 0.033). In conclusion, staged revascularization may be the preferred approach in patients with >1 CTO lesions requiring revascularization, as treatment during a single procedure was associated with higher risk for periprocedural complications.

Original language	English (US)
Pages (from-to)	381-387
Number of pages	7
Journal	American Journal of Cardiology
Volume	122
Issue number	3
DOIs	https://doi.org/10.1016/j.amjcard.2018.04.021
State	Published - Aug 1 2018

Bibliographical note

Funding Information:
Khaldoon Alaswaad, MD: consulting fees from Terumo and Boston Scientific; consultant, no financial, Abbott Laboratories. Dimitri Karmpaliotis, MD, PhD: Speaker honoraria: Abbott Vascular, Boston Scientific, Medtronic, and Vascular Solutions. Farouc A. Jaffer, MD, PhD: Consultant: Abbott Vascular and Boston Scientific. Research grant: Canon, Siemens and National Institutes of Health. Robert W. Yeh, MD: Career Development Award (1K23HL118138) from the National Heart, Lung, and Blood Institute. Mitul Patel, MD: speakers' bureau for Astra Zeneca. Ehtisham Mahmud, MD: consulting fees from Medtronic and Corindus; speaker's fees from Medtronic, Corindus, and Abbott Vascular; educational program fees from Abbott Vascular; and clinical events committee fees from St. Jude. M. Nicholas Burke, MD: consulting and speaker honoraria from Abbott Vascular and Boston Scientific. R. Michael Wyman, MD: Honoraria/consulting/speaking fees from Boston Scientific, Abbott Vascular, and Asahi. David E. Kandzari, MD: research/grant support and consulting honoraria from Boston Scientific and Medtronic Cardiovascular, and research/grant support from Abbott. Santiago Garcia, MD: consulting fees from Medtronic. Jeffrey W. Moses, MD: consultant to Boston Scientific and Abiomed. Nicholas J. Lembo, MD: speaker bureau: Medtronic; advisory board Abbott Vascular and Medtronic. Manish Parikh, MD: speaker bureau: Abbot Vascular, Medtronic, CSI, BSC, Trireme; advisory boards: Medtronic, Abbott Vascular, Philips. Ajay J. Kirtane, MD: Institutional research grants to Columbia University from Boston Scientific, Medtronic, Abbott Vascular, Abiomed, St. Jude Medical, Vascular Dynamics, Glaxo SmithKline, and Eli Lilly. Ziad A. Ali, MD: consultant fees/honoraria from St. Jude Medical, and AstraZeneca Pharmaceuticals; ownership interest/partnership/principal in Shockwave Medical and VitaBx Inc; and research grants from Medtronic and St. Jude Medical Bavana V. Rangan, BDS, MPH: Research grants from InfraReDx, Inc., and The Spectranetics Corporation. Subhash Banerjee, MD: research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Medtronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel. Emmanouil S. Brilakis, MD, PhD: consulting/speaker honoraria from Abbott Vascular, ACIST, Amgen, Asahi, CSI, Elsevier, GE Healthcare, Medicure, Medtronic, and Nitiloop; research support from Boston Scientific and Osprey. Board of Directors: Cardiovascular Innovations Foundation. Board of Trustees: Society of Cardiovascular Angiography and Interventions.

Publisher Copyright:
© 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.amjcard.2018.04.021

Find It

Find It at U of M Libraries

Cite this

Tajti, P., Alaswad, K., Karmpaliotis, D., Jaffer, F. A., Yeh, R. W., Patel, M., Mahmud, E., Choi, J. W., Burke, M. N., Doing, A. H., Toma, C., Uretsky, B., Holper, E., Wyman, R. M., Kandzari, D. E., Garcia, S., Krestyaninov, O., Khelimskii, D., Koutouzis, M., ... Brilakis, E. S. (2018). In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure. American Journal of Cardiology, 122(3), 381-387. https://doi.org/10.1016/j.amjcard.2018.04.021

Tajti, P, Alaswad, K, Karmpaliotis, D, Jaffer, FA, Yeh, RW, Patel, M, Mahmud, E, Choi, JW, Burke, MN, Doing, AH, Toma, C, Uretsky, B, Holper, E, Wyman, RM, Kandzari, DE, Garcia, S, Krestyaninov, O, Khelimskii, D, Koutouzis, M, Tsiafoutis, I, Jaber, W, Samady, H, Moses, JW, Lembo, NJ, Parikh, M, Kirtane, AJ, Ali, ZA, Doshi, D, Xenogiannis, I, Rangan, BV, Ungi, I, Banerjee, S & Brilakis, ES 2018, 'In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure', American Journal of Cardiology, vol. 122, no. 3, pp. 381-387. https://doi.org/10.1016/j.amjcard.2018.04.021

@article{2d7f4daa3a164d478feae178d9bbf711,

title = "In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure",

abstract = "The frequency and outcomes of patients who underwent chronic total occlusion (CTO) percutaneous coronary intervention (PCI) of more than one CTO during the same procedure have received limited study. We compared the clinical and angiographic characteristics and procedural outcomes of patients who underwent treatment of single versus >1 CTOs during the same procedure in 20 centers from the United States, Europe, and Russia. A total of 2,955 patients were included: mean age was 65 ± 10 years and 85% were men with high prevalence of previous myocardial infarction (46%), and previous coronary artery bypass graft surgery (33%). More than one CTO lesions were attempted during the same procedure in 58 patients (2.0%) and 70% of them were located in different major epicardial arteries. Compared with patients who underwent PCI of a single CTO, those who underwent PCI of >1 CTOs during the same procedure had similar J-CTO (2.4 ± 1.3 vs 2.5 ± 1.3, p = 0.579) and Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (1.5 ± 1.2 vs 1.3 ± 1.0 p = 0.147) scores. The multi-CTO PCI group had similar technical success (86% vs 87%, p = 0.633), but higher risk of in-hospital major complications (10.3% vs 2.7%, p = 0.005), and consequently numerically lower procedural success (79% vs 85%, p = 0.197). The multi-CTO PCI group had higher in-hospital mortality (5.2% vs 0.5%, p = 0.005) and stroke (5.2%vs 0.2%, p <0.001), longer procedure duration (162 [117 to 242] vs 122 [80 to 186] minutes, p <0.001) and higher radiation dose (3.6 [2.1 to 6.4] vs 2.9 [1.7 to 4.7] Gray, p = 0.033). In conclusion, staged revascularization may be the preferred approach in patients with >1 CTO lesions requiring revascularization, as treatment during a single procedure was associated with higher risk for periprocedural complications.",

author = "Peter Tajti and Khaldoon Alaswad and Dimitri Karmpaliotis and Jaffer, {Farouc A.} and Yeh, {Robert W.} and Mitul Patel and Ehtisham Mahmud and Choi, {James W.} and Burke, {M. Nicholas} and Doing, {Anthony H.} and Catalin Toma and Barry Uretsky and Elizabeth Holper and Wyman, {R. Michael} and Kandzari, {David E.} and Santiago Garcia and Oleg Krestyaninov and Dmitrii Khelimskii and Michalis Koutouzis and Ioannis Tsiafoutis and Wissam Jaber and Habib Samady and Moses, {Jeffrey W.} and Lembo, {Nicholas J.} and Manish Parikh and Kirtane, {Ajay J.} and Ali, {Ziad A.} and Darshan Doshi and Iosif Xenogiannis and Rangan, {Bavana V.} and Imre Ungi and Subhash Banerjee and Brilakis, {Emmanouil S.}",

note = "Funding Information: Khaldoon Alaswaad, MD: consulting fees from Terumo and Boston Scientific; consultant, no financial, Abbott Laboratories. Dimitri Karmpaliotis, MD, PhD: Speaker honoraria: Abbott Vascular, Boston Scientific, Medtronic, and Vascular Solutions. Farouc A. Jaffer, MD, PhD: Consultant: Abbott Vascular and Boston Scientific. Research grant: Canon, Siemens and National Institutes of Health. Robert W. Yeh, MD: Career Development Award (1K23HL118138) from the National Heart, Lung, and Blood Institute. Mitul Patel, MD: speakers' bureau for Astra Zeneca. Ehtisham Mahmud, MD: consulting fees from Medtronic and Corindus; speaker's fees from Medtronic, Corindus, and Abbott Vascular; educational program fees from Abbott Vascular; and clinical events committee fees from St. Jude. M. Nicholas Burke, MD: consulting and speaker honoraria from Abbott Vascular and Boston Scientific. R. Michael Wyman, MD: Honoraria/consulting/speaking fees from Boston Scientific, Abbott Vascular, and Asahi. David E. Kandzari, MD: research/grant support and consulting honoraria from Boston Scientific and Medtronic Cardiovascular, and research/grant support from Abbott. Santiago Garcia, MD: consulting fees from Medtronic. Jeffrey W. Moses, MD: consultant to Boston Scientific and Abiomed. Nicholas J. Lembo, MD: speaker bureau: Medtronic; advisory board Abbott Vascular and Medtronic. Manish Parikh, MD: speaker bureau: Abbot Vascular, Medtronic, CSI, BSC, Trireme; advisory boards: Medtronic, Abbott Vascular, Philips. Ajay J. Kirtane, MD: Institutional research grants to Columbia University from Boston Scientific, Medtronic, Abbott Vascular, Abiomed, St. Jude Medical, Vascular Dynamics, Glaxo SmithKline, and Eli Lilly. Ziad A. Ali, MD: consultant fees/honoraria from St. Jude Medical, and AstraZeneca Pharmaceuticals; ownership interest/partnership/principal in Shockwave Medical and VitaBx Inc; and research grants from Medtronic and St. Jude Medical Bavana V. Rangan, BDS, MPH: Research grants from InfraReDx, Inc., and The Spectranetics Corporation. Subhash Banerjee, MD: research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Medtronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel. Emmanouil S. Brilakis, MD, PhD: consulting/speaker honoraria from Abbott Vascular, ACIST, Amgen, Asahi, CSI, Elsevier, GE Healthcare, Medicure, Medtronic, and Nitiloop; research support from Boston Scientific and Osprey. Board of Directors: Cardiovascular Innovations Foundation. Board of Trustees: Society of Cardiovascular Angiography and Interventions. Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = aug,

day = "1",

doi = "10.1016/j.amjcard.2018.04.021",

language = "English (US)",

volume = "122",

pages = "381--387",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure

AU - Tajti, Peter

AU - Alaswad, Khaldoon

AU - Karmpaliotis, Dimitri

AU - Jaffer, Farouc A.

AU - Yeh, Robert W.

AU - Patel, Mitul

AU - Mahmud, Ehtisham

AU - Choi, James W.

AU - Burke, M. Nicholas

AU - Doing, Anthony H.

AU - Toma, Catalin

AU - Uretsky, Barry

AU - Holper, Elizabeth

AU - Wyman, R. Michael

AU - Kandzari, David E.

AU - Garcia, Santiago

AU - Krestyaninov, Oleg

AU - Khelimskii, Dmitrii

AU - Koutouzis, Michalis

AU - Tsiafoutis, Ioannis

AU - Jaber, Wissam

AU - Samady, Habib

AU - Moses, Jeffrey W.

AU - Lembo, Nicholas J.

AU - Parikh, Manish

AU - Kirtane, Ajay J.

AU - Ali, Ziad A.

AU - Doshi, Darshan

AU - Xenogiannis, Iosif

AU - Rangan, Bavana V.

AU - Ungi, Imre

AU - Banerjee, Subhash

AU - Brilakis, Emmanouil S.

N1 - Funding Information: Khaldoon Alaswaad, MD: consulting fees from Terumo and Boston Scientific; consultant, no financial, Abbott Laboratories. Dimitri Karmpaliotis, MD, PhD: Speaker honoraria: Abbott Vascular, Boston Scientific, Medtronic, and Vascular Solutions. Farouc A. Jaffer, MD, PhD: Consultant: Abbott Vascular and Boston Scientific. Research grant: Canon, Siemens and National Institutes of Health. Robert W. Yeh, MD: Career Development Award (1K23HL118138) from the National Heart, Lung, and Blood Institute. Mitul Patel, MD: speakers' bureau for Astra Zeneca. Ehtisham Mahmud, MD: consulting fees from Medtronic and Corindus; speaker's fees from Medtronic, Corindus, and Abbott Vascular; educational program fees from Abbott Vascular; and clinical events committee fees from St. Jude. M. Nicholas Burke, MD: consulting and speaker honoraria from Abbott Vascular and Boston Scientific. R. Michael Wyman, MD: Honoraria/consulting/speaking fees from Boston Scientific, Abbott Vascular, and Asahi. David E. Kandzari, MD: research/grant support and consulting honoraria from Boston Scientific and Medtronic Cardiovascular, and research/grant support from Abbott. Santiago Garcia, MD: consulting fees from Medtronic. Jeffrey W. Moses, MD: consultant to Boston Scientific and Abiomed. Nicholas J. Lembo, MD: speaker bureau: Medtronic; advisory board Abbott Vascular and Medtronic. Manish Parikh, MD: speaker bureau: Abbot Vascular, Medtronic, CSI, BSC, Trireme; advisory boards: Medtronic, Abbott Vascular, Philips. Ajay J. Kirtane, MD: Institutional research grants to Columbia University from Boston Scientific, Medtronic, Abbott Vascular, Abiomed, St. Jude Medical, Vascular Dynamics, Glaxo SmithKline, and Eli Lilly. Ziad A. Ali, MD: consultant fees/honoraria from St. Jude Medical, and AstraZeneca Pharmaceuticals; ownership interest/partnership/principal in Shockwave Medical and VitaBx Inc; and research grants from Medtronic and St. Jude Medical Bavana V. Rangan, BDS, MPH: Research grants from InfraReDx, Inc., and The Spectranetics Corporation. Subhash Banerjee, MD: research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Medtronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel. Emmanouil S. Brilakis, MD, PhD: consulting/speaker honoraria from Abbott Vascular, ACIST, Amgen, Asahi, CSI, Elsevier, GE Healthcare, Medicure, Medtronic, and Nitiloop; research support from Boston Scientific and Osprey. Board of Directors: Cardiovascular Innovations Foundation. Board of Trustees: Society of Cardiovascular Angiography and Interventions. Publisher Copyright: © 2018

PY - 2018/8/1

Y1 - 2018/8/1

N2 - The frequency and outcomes of patients who underwent chronic total occlusion (CTO) percutaneous coronary intervention (PCI) of more than one CTO during the same procedure have received limited study. We compared the clinical and angiographic characteristics and procedural outcomes of patients who underwent treatment of single versus >1 CTOs during the same procedure in 20 centers from the United States, Europe, and Russia. A total of 2,955 patients were included: mean age was 65 ± 10 years and 85% were men with high prevalence of previous myocardial infarction (46%), and previous coronary artery bypass graft surgery (33%). More than one CTO lesions were attempted during the same procedure in 58 patients (2.0%) and 70% of them were located in different major epicardial arteries. Compared with patients who underwent PCI of a single CTO, those who underwent PCI of >1 CTOs during the same procedure had similar J-CTO (2.4 ± 1.3 vs 2.5 ± 1.3, p = 0.579) and Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (1.5 ± 1.2 vs 1.3 ± 1.0 p = 0.147) scores. The multi-CTO PCI group had similar technical success (86% vs 87%, p = 0.633), but higher risk of in-hospital major complications (10.3% vs 2.7%, p = 0.005), and consequently numerically lower procedural success (79% vs 85%, p = 0.197). The multi-CTO PCI group had higher in-hospital mortality (5.2% vs 0.5%, p = 0.005) and stroke (5.2%vs 0.2%, p <0.001), longer procedure duration (162 [117 to 242] vs 122 [80 to 186] minutes, p <0.001) and higher radiation dose (3.6 [2.1 to 6.4] vs 2.9 [1.7 to 4.7] Gray, p = 0.033). In conclusion, staged revascularization may be the preferred approach in patients with >1 CTO lesions requiring revascularization, as treatment during a single procedure was associated with higher risk for periprocedural complications.

AB - The frequency and outcomes of patients who underwent chronic total occlusion (CTO) percutaneous coronary intervention (PCI) of more than one CTO during the same procedure have received limited study. We compared the clinical and angiographic characteristics and procedural outcomes of patients who underwent treatment of single versus >1 CTOs during the same procedure in 20 centers from the United States, Europe, and Russia. A total of 2,955 patients were included: mean age was 65 ± 10 years and 85% were men with high prevalence of previous myocardial infarction (46%), and previous coronary artery bypass graft surgery (33%). More than one CTO lesions were attempted during the same procedure in 58 patients (2.0%) and 70% of them were located in different major epicardial arteries. Compared with patients who underwent PCI of a single CTO, those who underwent PCI of >1 CTOs during the same procedure had similar J-CTO (2.4 ± 1.3 vs 2.5 ± 1.3, p = 0.579) and Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (1.5 ± 1.2 vs 1.3 ± 1.0 p = 0.147) scores. The multi-CTO PCI group had similar technical success (86% vs 87%, p = 0.633), but higher risk of in-hospital major complications (10.3% vs 2.7%, p = 0.005), and consequently numerically lower procedural success (79% vs 85%, p = 0.197). The multi-CTO PCI group had higher in-hospital mortality (5.2% vs 0.5%, p = 0.005) and stroke (5.2%vs 0.2%, p <0.001), longer procedure duration (162 [117 to 242] vs 122 [80 to 186] minutes, p <0.001) and higher radiation dose (3.6 [2.1 to 6.4] vs 2.9 [1.7 to 4.7] Gray, p = 0.033). In conclusion, staged revascularization may be the preferred approach in patients with >1 CTO lesions requiring revascularization, as treatment during a single procedure was associated with higher risk for periprocedural complications.

UR - http://www.scopus.com/inward/record.url?scp=85049323702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049323702&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2018.04.021

DO - 10.1016/j.amjcard.2018.04.021

M3 - Article

C2 - 30201106

AN - SCOPUS:85049323702

SN - 0002-9149

VL - 122

SP - 381

EP - 387

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 3

ER -

In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this